1h Free Analyst Time
Traumatic Brain Injury - Pipeline Review, H2 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Pipeline Review, H2 2020, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.
Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 8, 13, 2, 96 and 16 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.
Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionTraumatic Brain Injury - Overview
Traumatic Brain Injury - Therapeutics Development
Traumatic Brain Injury - Therapeutics Assessment
Traumatic Brain Injury - Companies Involved in Therapeutics Development
Traumatic Brain Injury - Drug Profiles
Traumatic Brain Injury - Dormant Projects
Traumatic Brain Injury - Discontinued Products
Traumatic Brain Injury - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Traumatic Brain Injury, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Traumatic Brain Injury - Pipeline by Abliva AB, H2 2020
- Traumatic Brain Injury - Pipeline by Acelerox LLC, H2 2020
- Traumatic Brain Injury - Pipeline by AegisCN LLC, H2 2020
- Traumatic Brain Injury - Pipeline by AivoCode LLP, H2 2020
- Traumatic Brain Injury - Pipeline by ALSP Inc, H2 2020
- Traumatic Brain Injury - Pipeline by AlzeCure Pharma AB, H2 2020
- Traumatic Brain Injury - Pipeline by AMAG Pharmaceuticals Inc, H2 2020
- Traumatic Brain Injury - Pipeline by American CryoStem Corp, H2 2020
- Traumatic Brain Injury - Pipeline by Anagin Inc, H2 2020
- Traumatic Brain Injury - Pipeline by Anida Pharma Inc, H2 2020
- Traumatic Brain Injury - Pipeline by Annovis Bio Inc, H2 2020
- Traumatic Brain Injury - Pipeline by AntiRadical Therapeutics LLC, H2 2020
- Traumatic Brain Injury - Pipeline by Anvyl LLC, H2 2020
- Traumatic Brain Injury - Pipeline by Aptinyx Inc, H2 2020
- Traumatic Brain Injury - Pipeline by Astrocyte Pharmaceuticals Inc, H2 2020
- Traumatic Brain Injury - Pipeline by Athersys Inc, H2 2020
- Traumatic Brain Injury - Pipeline by Avanir Pharmaceuticals Inc, H2 2020
- Traumatic Brain Injury - Pipeline by Bessor Pharma LLC, H2 2020
- Traumatic Brain Injury - Pipeline by Beyond Barriers Therapeutics Inc, H2 2020
- Traumatic Brain Injury - Pipeline by Biogen Inc, H2 2020
- Traumatic Brain Injury - Pipeline by BioIncept LLC, H2 2020
- Traumatic Brain Injury - Pipeline by Bioquark Inc, H2 2020
- Traumatic Brain Injury - Pipeline by Brain-Gen LLC, H2 2020
- Traumatic Brain Injury - Pipeline by CalciMedica Inc, H2 2020
- Traumatic Brain Injury - Pipeline by CavoGene LifeSciences, H2 2020
- Traumatic Brain Injury - Dormant Projects, H2 2020
- Traumatic Brain Injury - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Traumatic Brain Injury, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abliva AB
- Acelerox LLC
- AegisCN LLC
- AivoCode LLP
- ALSP Inc
- AlzeCure Pharma AB
- AMAG Pharmaceuticals Inc
- American CryoStem Corp
- Anagin Inc
- Anida Pharma Inc
- Annovis Bio Inc
- AntiRadical Therapeutics LLC
- Anvyl LLC
- Aptinyx Inc
- Astrocyte Pharmaceuticals Inc
- Athersys Inc
- Avanir Pharmaceuticals Inc
- Bessor Pharma LLC
- Beyond Barriers Therapeutics Inc
- Biogen Inc
- BioIncept LLC
- Bioquark Inc
- Brain-Gen LLC
- CalciMedica Inc
- CavoGene LifeSciences
- CellCure
- Cellvation Inc
- CereSpir Inc
- Chimerix Inc
- Chrysalis BioTherapeutics Inc
- Cognosci Inc
- Complement Pharma BV
- DeckTherapeutics Inc
- Deha Pharmaceutical LLC
- Eagle Pharmaceuticals Inc
- Eisai Co Ltd
- Emerald Organic Products Inc
- Epigen Biosciences Inc
- Expesicor Inc
- Fortuna Fix Inc
- GABA Therapeutics Inc
- GNT Pharma Co Ltd
- Hemarina SA
- Hibernaid Inc
- Hillhurst Biopharmaceuticals Inc
- Hope Biosciences LLC
- Hoverink Biotechnologies Inc
- ImmunoChem Therapeutics LLC
- Impression Healthcare Ltd
- Inflammatory Response Research Inc
- International Stem Cell Corp
- Ischemix Inc
- JT Pharmaceuticals Inc
- Kalytera Therapeutics Inc
- KannaLife Sciences Inc
- Levolta Pharmaceuticals Inc
- M et P Pharma AG
- Mapreg SAS
- Mercaptor Discoveries Inc
- MetVital Inc
- NeuExcell Therapeutics Inc
- NeurAegis Inc
- Neuren Pharmaceuticals Ltd
- NeurExo Sciences LLC
- Neurodon LLC
- Neuronasal LLC
- NeuroNascent Inc
- Neuroplast BV
- NeuroTheranostics Inc
- NeuroTrauma Sciences LLC
- Neurotrope Bioscience Inc
- New World Laboratories Inc
- NoNO Inc
- NuvOx Pharma LLC
- Nyrada Inc
- OncoSynergy Inc
- Orpheris Inc
- Oxeia Biopharmaceuticals Inc
- Peptron Inc
- PharmatrophiX Inc
- Pinteon Therapeutics Inc
- Praetego Inc
- Prevacus Inc
- ProNeurogen Inc
- ProThera Biologics Inc
- Protheragen Inc
- Qrons Inc
- RegeneRx Biopharmaceuticals Inc
- Resolys Bio Inc
- RHNanopharmacuticals LLC
- Rubicon Biotechnology Inc
- Samus Therapeutics Inc
- SanBio Company Limited
- Seneca Biopharma Inc
- Shinkei Therapeutics LLC
- Silver Creek Pharmaceuticals Inc
- Spinogenix Inc
- STATegics Inc
- Stemedica Cell Technologies Inc
- Swedish Orphan Biovitrum AB
- Tassili Life Sciences Corp
- Tellus Therapeutics Inc
- Tetra Therapeutics
- Thera Neuropharma Inc
- Therapeutic Solutions International Inc
- Therapix Biosciences Ltd
- Theratome Bio Inc
- TikoMed AB
- Tria Bioscience Corp
- vasopharm GmbH
- VG Life Sciences Inc
- Virogenomics BioDevelopment Inc
- Xcelthera INC
- Xonovo Inc
- ZyVersa Therapeutics Inc
